Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease
Switching to subcutaneous infliximab maintenance therapy was associated with high treatment persistence, a stable disease course, increased infliximab concentrations, and an acceptable safety profile.
Authors
- Perttu Arkkila (ORCID: https://orcid.org/0000-0003-2194-0424)
- Clas-Göran af Björkesten (ORCID: https://orcid.org/0000-0003-3406-8612)
- Kimmo Salminen (ORCID: https://orcid.org/0000-0001-5518-9240)
- Taina Sipponen (ORCID: https://orcid.org/0000-0002-8069-5273)
- Eliisa Löyttyniemi (ORCID: https://orcid.org/0000-0002-7278-6511)
- Sara Kolehmainen (ORCID: https://orcid.org/0009-0003-5176-9709)
- Jaakko Rautakorpi (ORCID: https://orcid.org/0000-0003-4361-6764)
Institutions
- University of Helsinki (FI)
- University of Turku (FI)
- Helsinki University Hospital (FI)
- Turku University Hospital (FI)
Publication Details
- Journal
- Digestive Diseases and Sciences
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1007/s10620-025-08876-5
- Citations
- 4
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 7.27
Funders
- Mary och Georg C. Ehrnrooths Stiftelse
- Turun Yliopisto